News
CEGX Team presents at AGBT 2023
Representatives from our R&D team presented 3 posters at the Advances in Genome Biology & Technology General Meeting in Hollywood, Florida.
FEB 2023
5 Letter sequencing & tangible improvements to health care
CEGX CSO Joanna Holbrook recently appeared on Precision Medicine Forum Podcast
Nov 2022
CEGX Team Published in Nature Biotechnology!
We are extremely proud to announce that our paper 'Simultaneous sequencing of genetic and epigenetic bases in DNA’ has been published by the journal Nature Biotechnology.
FEB 2023
CEGX presents sequencing technology at EACR Seville
Innovative Cancer Science 'CEGX scientists discussed novel sequencing technology for early cancer detection'
June 2022
Customer Interview - Cambridge Epigenetix - Analytik Ltd
We had the opportunity to speak with Dr. Gary Yalloway and Dr. Julia Vivian, Senior Scientists at Cambridge Epigenetix on LM20 Microfluidizer®.
Nov 2022
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health
June 2022
CEGX presents sequencing technology at Biology of Genomes 2022
CEGX scientists discussed novel technology at genomics conference in Cold Spring Harbour Laboratory
May 2022
Guardian Epigenetics Article
Epigenetics, the misunderstood science that could shed new light on ageing
Oct 2021
Series B funding – Google Ventures
Google Ventures leads $21M Series B in bioscience company Cambridge Epigenetix
March 2016
Trinity in Japan Video Interview
Sir Shankar Balasubramanian, inventor of Next Generation DNA Sequencing (NGS)
Oct 2021
Headquarters
- The Trinity Building, Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom
- info@cambridge-epigenetix.com
- Careers: jobs@cegx.co.uk
- +44 (0) 1223 800 700
Copyright © 2022 Cambridge Epigenetix, All rights reserved.